Cardiovascular Complications in HemodialysisNCT07519785
Prognostic Value of PLR On Cardiovascular Complications in Chronic Hemodialysis Patients
An observational study of Cardiovascular Complications in Hemodialysis, run by Minia University at 1 site in Egypt.
Trial summary
Prognostic value of platelet to lymphocyte ratio on cardiovascular complications in chronic hemodialysis patients this study was done to determine the prognostic value of PLR on cardiovascular complications like vascular calcifications and atherosclerosis in carotid and coronary arteries in chronic hemodialysis… Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Complications in Hemodialysis
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 4 Jan 2024to 4 Aug 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: patients undergoing hemodialysis for more than 3 months
Who may be able to join
- patients undergoing hemodialysis for more than 3 months who agreed to be included in the study
Who cannot join
- We are going to exclude patients who have:
- Younger than 18 year- old or Older than 75 year-old,
- Patients with positive serum marker of anti-hepatitis C virus (anti-HCV), hepatitis B surface antigen (HBsAg) and human immunodeficiency virus (HIV).
- Alcohol or illicit drug abusers.
- Inflammatory state due to infection,
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prognostic Value of the Platelet to Lymphocyte Ratio on Cardiovascular Complications in Chronic Hemodialysis Patients
Prognostic value of platelet to lymphocyte ratio on cardiovascular complications in chronic hemodialysis patients this study was done to determine the prognostic value of PLR on cardiovascular complications like vascular calcifications and atherosclerosis in carotid and coronary arteries in chronic hemodialysis patients
Read the detailed description
Prognostic value of platelet to lymphocyte ratio on cardiovascular complications in chronic hemodialysis patients this study was done to determine the prognostic value of PLR on cardiovascular complications like vascular calcifications and atherosclerosis in carotid and coronary arteries as these complications are common and well-known causes of morbidity and mortality in chronic hemodialysis patients
- Keywords
- platelet to lymphocyte ratio
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| disease group | 60 patients of ESKD on maintenance hemodialysis were investigated for platelet to lymphocyte ratio, S.PTH , S.Ca , S.Phosp Echocardiography and carotid duplex | |
| Healthy control group | 20 healthy persons were investigated for platelet to lymphocyte ratio to be compared with the disease group results |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the association between platelet-to-lymphocyte ratio and cardiovascular complications in patients on chronic maintenance hemodialysis.
Primary Outcome Association between PLR and cardiovascular complications in chronic hemodialysis patients.
Secondary Outcomes optimal PLR cutoff for cardiovascular complication prediction relation of PLR to individual cardiovascular diagnoses relation of PLR to cardiovascular hospitalization relation of PLR to cardiovascular mortality
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2026
- Study start4 Jan 2024
- Primary completion4 Jun 2024
- Study completion4 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular Complications in HemodialysisStudies of the same condition, open and under way.
- More trials run by Minia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Minia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hanaa Mohammad Aly, Minia University
- Investigators
- Hassan Mohammad Mohyedin, Professor of internal medicine, Study chair, faculty of medicine elminya university
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07519785
- Sponsor's protocol ID
- PLR
- Status last verified
- Apr 2026
- First submitted
- 3 Apr 2026
- Last updated
- 13 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: privacy
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Value of the Platelet to Lymphocyte Ratio on Cardiovascular Complications in Chronic Hemodialysis Patients
- ClinicalTrials.gov ID
- NCT07519785
- Acronym / sponsor ID
- PLR
- Keywords
- platelet to lymphocyte ratio
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Minia UniversityUniversity, hospital or other
- Study start
- 4 Jan 2024 (actual)
- Primary completion
- 4 Jun 2024 (actual)
- Study completion
- 4 Aug 2024 (actual)
- First posted
- 9 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prognostic value of platelet to lymphocyte ratio on cardiovascular complications in chronic hemodialysis patients this study was done to determine the prognostic value of PLR on cardiovascular complications like vascular calcifications and atherosclerosis in carotid and coronary arteries in chronic hemodialysis patients
Detailed description
Prognostic value of platelet to lymphocyte ratio on cardiovascular complications in chronic hemodialysis patients this study was done to determine the prognostic value of PLR on cardiovascular complications like vascular calcifications and atherosclerosis in carotid and coronary arteries as these complications are common and well-known causes of morbidity and mortality in chronic hemodialysis patients
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| disease group | – | –60 patients of ESKD on maintenance hemodialysis were investigated for platelet to lymphocyte ratio, S.PTH , S.Ca , S.Phosp Echocardiography and carotid duplex |
| Healthy control group | – | –20 healthy persons were investigated for platelet to lymphocyte ratio to be compared with the disease group results |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- patients undergoing hemodialysis for more than 3 months
Key inclusion criteria (1 listed)
- patients undergoing hemodialysis for more than 3 months who agreed to be included in the study
Key exclusion criteria (5 listed)
- We are going to exclude patients who have:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To evaluate the association between platelet-to-lymphocyte ratio and cardiovascular complications in patients on chronic maintenance hemodialysis.
Time frame: 6 months
Primary Outcome Association between PLR and cardiovascular complications in chronic hemodialysis patients. Secondary Outcomes optimal PLR cutoff for cardiovascular complication prediction relation of PLR to individual cardiovascular diagnoses relation of PLR to cardiovascular hospitalization relation of PLR to cardiovascular mortality
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
- PLR Prognostic ValueLink provided by the sponsor.
- Individual participant dataSharing planned: No. privacy
Related trials for Cardiovascular Complications in Hemodialysis
Not yet recruitingObservational study
Malnutrition and Sarcopenia in Adults With Chronic Kidney Disease in Tunisia
Malnutrition, Sarcopenia
RecruitingPhase 1
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
End-Stage Kidney Disease (ESKD)
Not yet recruiting
DialysisBot: AI Chatbot for Hemodialysis Self-Management
Chatbot-Based Training, Hemodialysis
Active, not recruiting
Deep Breathing Relaxation and Lemongrass Aromatherapy on Pain
Chronic Kidney Disease; End-Stage Renal Disease; Hemodialysis; Pain; Anxiety
Active, not recruitingObservational study
Cardiovascular and Bone Mineral Markers in Dialysis Patients and Healthy Controls
End-Stage Kidney Disease (ESKD), Hemodialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hassan Mohammad Mohyedin, Professor of internal medicine study chair
faculty of medicine elminya university
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Complications in Hemodialysis, run by Minia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the association between platelet-to-lymphocyte ratio and cardiovascular complications in patients on chronic maintenance hemodialysis. (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.